WO2004017897A2 - Aripiprazole complex formulation and method - Google Patents

Aripiprazole complex formulation and method Download PDF

Info

Publication number
WO2004017897A2
WO2004017897A2 PCT/US2003/025573 US0325573W WO2004017897A2 WO 2004017897 A2 WO2004017897 A2 WO 2004017897A2 US 0325573 W US0325573 W US 0325573W WO 2004017897 A2 WO2004017897 A2 WO 2004017897A2
Authority
WO
WIPO (PCT)
Prior art keywords
formulation
aripiprazole
cyclodextrin
acid
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/025573
Other languages
French (fr)
Other versions
WO2004017897A3 (en
Inventor
Manoj Nerurkar
Vijay Naringrekar
Mark Dominick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31946748&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2004017897(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to CA2495864A priority Critical patent/CA2495864C/en
Priority to YU20050118A priority patent/RS51903B/en
Priority to MXPA05001865A priority patent/MXPA05001865A/en
Priority to DK03751859T priority patent/DK1542668T3/en
Priority to JP2004531017A priority patent/JP4729306B2/en
Priority to EP03751859A priority patent/EP1542668B1/en
Priority to NZ537995A priority patent/NZ537995A/en
Priority to AT03751859T priority patent/ATE428423T1/en
Priority to DE60327225T priority patent/DE60327225D1/en
Priority to HRP20050149AA priority patent/HRP20050149B1/en
Priority to UAA200502492A priority patent/UA79984C2/en
Priority to BR0313602-7A priority patent/BR0313602A/en
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Priority to SI200331586T priority patent/SI1542668T1/en
Priority to AU2003269965A priority patent/AU2003269965B2/en
Publication of WO2004017897A2 publication Critical patent/WO2004017897A2/en
Publication of WO2004017897A3 publication Critical patent/WO2004017897A3/en
Priority to IL166623A priority patent/IL166623A/en
Priority to NO20050661A priority patent/NO333458B1/en
Priority to IS7701A priority patent/IS2878B/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Definitions

  • the present invention relates to an aripiprazole inclusion complex with a substituted- ⁇ -cyclodextrin, an aripiprazole formulation which includes aripiprazole in the form of the above inclusion complex, an injectable formulation which contains the above complex of aripiprazole, a method for reducing irritation normally caused by aripiprazole at an intramuscular injection site employing the above injectable formulation and a method for treating schizophrenia employing the above formulation.
  • U.S. Patent No. 5,006,528 to Oshiro et al. discloses 7-[(4-phenylpiperazino)- butoxy] carbostyrils, which include aripiprazole, as dopaminergic neurotransmitter antagonists.
  • aripiprazole When formulated as an intramuscular (IM) injectable solution, aripiprazole has been found to cause unacceptable (moderate to severe) tissue irritation at the muscular site with many water-miscible co-solvent systems, and water-immiscible solvent and co-solvent systems such as hexonoic acid: medium chain triglyceride (10:90), polyethylene glycol 400:ethanol:lactic acid (35:15:50), benzyl alcohol: sesame oil (10:90), benzyl alcoho medium chain triglyceride (10:90), benzyl alcohol :tributyrin (5:95), and polysorbate 80 in 25 mM tartaric acid.
  • IM intramuscular
  • Cyclodextrins are known for their use in increasing solubility of drugs. They function by forming inclusion complexes with hydrophobic molecules.
  • U.S. Patent Nos. 5,134,127 and 5,376,645 each to Stella et al. disclose sulfoalkyl ether cyclodextrin derivatives and their use as solubilizing agents for water-insoluble drugs for oral, intranasal or parenteral administration including intravenous and intramuscular.
  • Stella et al. disclose an inclusion complex of the water-insoluble drug and the sulfoalkyl ether cyclodextrin derivative and pharmaceutical compositions containing same.
  • Examples of sulfoalkyl ether cyclodextrin derivatives disclosed include mono-sulfobutyl ether of ⁇ -cyclodextrin and monosulfopropyl ether of ⁇ -cyclodextrin.
  • Examples of water-insoluble drugs are set out in column 7 starting at line 25 and include, among others, benzodiazepines, chlorpromazine, diazepam, mephorbarbital, methbarbital, nitrazepam, and phenobarbital.
  • U.S. Patent No. 6,232,304 to Kim et al. discloses inclusion complexes of aryl- heterocyclic salts such as the tartrate salt of ziprasidone in a cyclodextrin such as ⁇ - cyclodextrin sulfobutyl ether (SBECD), and hydroxypropyl- ⁇ -cyclodextrin (HPBCD), and use of such inclusion complexes in oral and parenteral formulations.
  • a cyclodextrin such as ⁇ - cyclodextrin sulfobutyl ether (SBECD), and hydroxypropyl- ⁇ -cyclodextrin (HPBCD)
  • Japanese Patent Application No. 09301867A2 dated November 25, 1997 discloses antidepressant compositions in the form of tablets containing aripiprazole.
  • EP1145711 Al dated October 17, 2001 discloses flash-melt oral dosage formulations containing aripiprazole.
  • U.S. Patent No. 5,904,929 to Uekama et al. discloses trans-mucosal and transdermal pharmaceutical compositions containing a drug and a peracylated cyclodextrin as a solubilizing agent.
  • drugs include antidepressants such as amitriptyline HCl, amoxapine, butriptyline HCl, clomipramine HCl, desipramine HCl, dothiepin HCl, doxepin HCl, fluoxetine, gepirone, imipramine, lithium carbonate, mianserin HCl, milnacipran, nortriptyline HCl and paroxetine HCl; anti- muscarinic agents such as atropine sulphate and hyoscine; sedating agents such as alprazolam, buspirone HCl, chlordiazepoxide HCl, chlorpromazine, clozapine, diazepam, flupenthixol HCl, fluphenazine, flurazepam, lorazepam, mazapertine, olanzapine, oxazepam, pimozide, pipamperone, piracetam,
  • an inclusion complex of aripiprazole in a substituted-beta-cyclodextrin is substantially more water-soluble relative to the non-complexed aripiprazole.
  • aripiprazole when aripiprazole is complexed with a substituted ⁇ -cyclodextrin such as sulfobutyl ether- ⁇ -cyclodextrin, it may be formulated as an injectable which delivers aripiprazole to the muscular site with unexpectedly diminished irritation as compared to injectables containing uncomplexed aripiprazole.
  • a pharmaceutical formulation which is formed of an inclusion complex of aripiprazole and a substituted- ⁇ -cyclodextrin, and a pharmaceutically acceptable carrier therefor.
  • the pharmaceutical formulation of the invention will be in the form of an aqueous parenteral or injectable formulation.
  • the pharmaceutical formulation of the invention may be in other dosage forms such as lyophilized injectable, oral (for example tablets, capsules, elixirs and the like), transdermal or transmucosal forms or inhalation forms.
  • a method for administering injectable aripiprazole without causing unacceptable irritation at the site of injection wherein the above described injectable formulation is administered, preferably intramuscularly, to a patient in need of treatment.
  • a method for treating schizophrenia which includes the step of administering to a patient in need of treatment the above described formulation, preferably in injectable form, without causing undue irritation at the site of injection, whether it be at a muscular site or other site.
  • Aripiprazole has poor water solubility and thus is difficult to formulate as an aqueous injectable.
  • the water-solubility of aripiprazole may be sufficiently increased to allow it to be formulated as an aqueous injectable by complexing aripiprazole with a substituted- ⁇ - cyclodextrin.
  • the cyclodextrin inhibits precipitation of the aripiprazole at the site of injection.
  • the aqueous injectable formulation containing the complex of aripiprazole and the substituted- ⁇ -cyclodextrin may be administered preferably intramuscularly without causing unacceptable irritation at the muscular site.
  • a host of water-miscible co-solvent systems and water-immiscible co-solvent systems have been found to be unacceptable as carriers for injectable aripiprazole formulations because of the unacceptable irritation profile of such formulations.
  • the aqueous injectable formulation of the invention delivers aripiprazole without causing unacceptable irritation at the site of injection.
  • the aripiprazole formulation in the form of an aqueous injectable will include an acid buffer and a base to adjust pH to desired levels.
  • substituted- ⁇ -cyclodextrin suitable for use herein refers to sulfobutyl ether ⁇ -cyclodextrin (SBECD) and hydroxypropyl- ⁇ -cyclodextrin (HPBCD), with SBECD being preferred.
  • SBECD sulfobutyl ether ⁇ -cyclodextrin
  • HPBCD hydroxypropyl- ⁇ -cyclodextrin
  • reduced irritation at the site of injection or at the muscular site refers to generally minimal to mild irritation which is acceptable to the patient and does not impact unfavorably on patient compliance.
  • aripiprazole will form a complex with the substituted- ⁇ -cyclodextrin which complex may be dissolved in water to form an injectable formulation.
  • physical mixtures of aripiprazole and the substituted- ⁇ -cyclodextrin are within the scope of the present invention as well.
  • the complex or the physical mixture may also be compressed into a tablet or may be filled into capsules.
  • the aripiprazole formulations of the invention may be formed of dry physical mixtures of aripiprazole and the substituted- ⁇ -cyclodextrin or dry inclusion complexes thereof which upon addition of water are reconstituted to form an aqueous injectable formulation.
  • the aqueous injectable formulation may be freeze dried and later reconstituted with water.
  • the inclusion complex in accordance with the invention may be pre-formed, formed in situ or formed in vivo (in the gastrointestional tract or the buccal cavity). All of the above are contemplated by the present invention.
  • the aripiprazole formulation of the invention in the form of an aqueous injectable will include an acid buffer to adjust pH of the aqueous injection within the range from about 3.5 to about 5.
  • acid buffers suitable for use herein include acids such as hydrochloric acid, sulfuric acid, phosphoric acid, hydrobromic acid and the like, and organic acids such as oxalic acid, maleic acid, fumaric acid, lactic acid, malic acid, tartaric acid, citric acid, benzoic acid, acetic acid, methanesulfonic acid, toluenesulfonic acid, benzenesulfonic acid, ethanesulfonic acid and the like. Acid salts of the above acids may be employed as well.
  • Preferred acids are tartaric acid, citric acid, and hydrochloric acid. Most preferred is tartaric acid.
  • the injectable formulation of the invention will have a pH within the range from about 3.5 to about 5, preferably from about 4 to about 4.6, and most preferably about 4.3.
  • the pH may be adjusted with a base such as an alkali metal hydroxide such as NaOH, KOH, or LiOH, preferably NaOH, or an alkaline earth metal hydroxide, such as Mg(OH) 2 or Ca(OH) 2 .
  • the substituted- ⁇ -cyclodextrin will be employed in a weight ratio to the aripiprazole within the range from about 5:1 to 400:1, preferably from about 10:1 to about 100:1.
  • each type of cyclodextrin employed requires a different ratio to inhibit or prevent precipitation of aripiprazole at the injection site.
  • the substituted- ⁇ -cyclodextrin will be SBECD which will be employed in a weight ratio to aripiprazole within the range from about 5 : 1 to about 400 : 1 , preferably from about 20 : 1 to about 40 : 1.
  • the cyclodextrin may be present in an amount greater than that needed to complex the aripiprazole since the additional cyclodextrin could aid in dissolution of the aripiprazole.
  • the aripiprazole will be present in the aqueous injectable formulation in an amount within the range from about 0.1 to about 2.5% by weight, preferably from about 0.2 to about 1.5 % by weight based on the total injectable formulation.
  • the aripiprazole will be present in the aqueous injectable formulation to provide from about 1 to about 20 mg/mL of formulation, preferably from about 1.5 to about 8 mg/mL of formulation.
  • formulations of the invention will provide
  • a preferred injectable formulation is as follows:
  • aripiprazole - in an amount to provide from about 1.5 to about 8 mg/mL of solution.
  • base to adjust pH preferably an alkali metal hydroxide, preferably NaOH - in an amount to adjust pH from about 4 to 4.6
  • the aripiprazole injectable formulation of the invention may be prepared as follows: Tartaric acid or other acid buffer is dissolved in water for injection.
  • the substituted- ⁇ -cyclodextrin preferably SBECD
  • Aripiprazole is then dissolved in the solution.
  • the pH of the solution is adjusted to within the range from about 3.5 to about 5, preferably about 4.3 by adding base, such as sodium hydroxide or other alkali metal hydroxide or alkaline earth metal hydroxide. Additional water for injection is added to obtain the desired batch volume.
  • the resulting solution is aseptically filtered, for example, through a 0.22 ⁇ membrane filter and filled into vials.
  • the vials are stopped and sealed and terminally sterilized.
  • the aqueous injectable formulation of the invention will provide an amount of aripiprazole of at least 2 mg aripiprazole/mL, preferably at least 5 mg aripiprazole/mL, when the amount of aripiprazole provided by the complex is measured at a cyclodextrin concentration of 5% w/v in water.
  • the aripiprazole formulations of the invention are used to treat schizophrenia in human patients.
  • the preferred dosage employed for the injectable formulations of the invention will be a 2 ml injection containing 7.5 mg aripiprazole/mL or a dose of 15 mg given three times daily at two hour intervals.
  • the injectable formulation is preferably administered intramuscularly although subcutaneous and intravenous injections are effective as well.
  • the following example represents a preferred embodiment of the invention.
  • a clear colorless aripiprazole injectable solution (2 mg aripiprazole/mL, 4 mg/vial) essentially free of particulate matter by visual inspection was prepared as follows.
  • a stainless steel batching vessel was charged with an appropriate amount of water for inj ection USP .
  • Aripiprazole 20 g was added to the batching vessel and stirring was continued until the aripiprazole was dissolved.
  • Sodium hydroxide IN was added to the above solution to adjust the pH thereof to about 4.3.
  • the above solution was aseptically filtered through a 0.22 ⁇ M membrane filter into a sterilized container 4 mg amounts of the above solution were aseptically filled into sterilized vials which were then aseptically stoppered with sterilized stoppers to seal the vials.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

An aripiprazole formulation is provided which includes the antipsychotic agent aripiprazole in the form of an inclusion complex in a b-cyclodextrin, preferably, sulfobutyl ether b-cyclodextrin (SBECD), which in the form of an injectable produces reversible generally minimal to mild irritation at the intramuscular injection site. A method for minimizing or reducing irritation caused by aripiprazole at an intramuscular injection site and a method for treating schizophrenia employing the above formulation are also provided.

Description

ARIPIPRAZOLE COMPLEX FORMULATION AND METHOD FIELD OF THE INVENTION
The present invention relates to an aripiprazole inclusion complex with a substituted-β-cyclodextrin, an aripiprazole formulation which includes aripiprazole in the form of the above inclusion complex, an injectable formulation which contains the above complex of aripiprazole, a method for reducing irritation normally caused by aripiprazole at an intramuscular injection site employing the above injectable formulation and a method for treating schizophrenia employing the above formulation.
BACKGROUND OF THE INVENTION
U.S. Patent No. 5,006,528 to Oshiro et al. discloses 7-[(4-phenylpiperazino)- butoxy] carbostyrils, which include aripiprazole, as dopaminergic neurotransmitter antagonists.
Aripiprazole which has the structure
Figure imgf000002_0001
is an atypical antipsychotic agent useful in treating schizoplirenia. It has poor aqueous solubility (<lμg/mL at room temperature). When formulated as an intramuscular (IM) injectable solution, aripiprazole has been found to cause unacceptable (moderate to severe) tissue irritation at the muscular site with many water-miscible co-solvent systems, and water-immiscible solvent and co-solvent systems such as hexonoic acid: medium chain triglyceride (10:90), polyethylene glycol 400:ethanol:lactic acid (35:15:50), benzyl alcohol: sesame oil (10:90), benzyl alcoho medium chain triglyceride (10:90), benzyl alcohol :tributyrin (5:95), and polysorbate 80 in 25 mM tartaric acid.
Cyclodextrins are known for their use in increasing solubility of drugs. They function by forming inclusion complexes with hydrophobic molecules.
Unfortunately, there are many drugs for which cyclodextrin complexation either is not possible or produces no apparent advantages as disclosed by J Szejtli, Cyclodextrins in Drug Formulations: Part II, Pharmaceutical Technology, 24-38, August, 1991.
U.S. Patent Nos. 5,134,127 and 5,376,645 each to Stella et al. disclose sulfoalkyl ether cyclodextrin derivatives and their use as solubilizing agents for water-insoluble drugs for oral, intranasal or parenteral administration including intravenous and intramuscular. Stella et al. disclose an inclusion complex of the water-insoluble drug and the sulfoalkyl ether cyclodextrin derivative and pharmaceutical compositions containing same. Examples of sulfoalkyl ether cyclodextrin derivatives disclosed include mono-sulfobutyl ether of β -cyclodextrin and monosulfopropyl ether of β -cyclodextrin. Examples of water-insoluble drugs are set out in column 7 starting at line 25 and include, among others, benzodiazepines, chlorpromazine, diazepam, mephorbarbital, methbarbital, nitrazepam, and phenobarbital.
U.S. Patent No. 6,232,304 to Kim et al. discloses inclusion complexes of aryl- heterocyclic salts such as the tartrate salt of ziprasidone in a cyclodextrin such as β- cyclodextrin sulfobutyl ether (SBECD), and hydroxypropyl-β -cyclodextrin (HPBCD), and use of such inclusion complexes in oral and parenteral formulations.
Japanese Patent Application No. 09301867A2 dated November 25, 1997 discloses antidepressant compositions in the form of tablets containing aripiprazole. EP1145711 Al dated October 17, 2001 (based on U.S. Application Serial No. 2000-547948 filed April 12, 2000) discloses flash-melt oral dosage formulations containing aripiprazole.
U.S. Patent No. 5,904,929 to Uekama et al. discloses trans-mucosal and transdermal pharmaceutical compositions containing a drug and a peracylated cyclodextrin as a solubilizing agent. Examples of drugs include antidepressants such as amitriptyline HCl, amoxapine, butriptyline HCl, clomipramine HCl, desipramine HCl, dothiepin HCl, doxepin HCl, fluoxetine, gepirone, imipramine, lithium carbonate, mianserin HCl, milnacipran, nortriptyline HCl and paroxetine HCl; anti- muscarinic agents such as atropine sulphate and hyoscine; sedating agents such as alprazolam, buspirone HCl, chlordiazepoxide HCl, chlorpromazine, clozapine, diazepam, flupenthixol HCl, fluphenazine, flurazepam, lorazepam, mazapertine, olanzapine, oxazepam, pimozide, pipamperone, piracetam, promazine, risperidone, selfotel, seroquel, sulpiride, temazepam, thiothixene, triazolam, trifluperidol and ziprasidone; anti-migraine drugs such as alniditan and sumatriptan; beta-adrenoreptor blocking agents such as atenolol, carvedilol, metoprolol, nebivolol and propranolol; anti-Parkinsonian drugs such as bromocryptine mesylate, levodopa and selegiline HCl; opioid analgesics such as buprenorphine HCl, codeine, dextromoramide and dihydrocodeine; parasympathomimetics such as galanthamine, neostigmine, physostymine, tacrine, donepezil, ENA 713 (exelon) and xanomeline; and vasodilators such as amlodipine, buflomedil, amyl nitrite, diltiazem, dipyridamole, glyceryl trinitrate, isosorbide dinitrate, lidoflazine, molsidomine, nicardipine, nifedipine, oxpentifylline and pentaerythritol tetranitrate.
BRIEF DESCRIPTION OF THE INVENTION
In accordance with the present invention, there is provided an inclusion complex of aripiprazole in a substituted-beta-cyclodextrin. It has been found that the inclusion complex of aripiprazole is substantially more water-soluble relative to the non-complexed aripiprazole. Surprisingly and unexpectedly, it has been found that when aripiprazole is complexed with a substituted β -cyclodextrin such as sulfobutyl ether-β-cyclodextrin, it may be formulated as an injectable which delivers aripiprazole to the muscular site with unexpectedly diminished irritation as compared to injectables containing uncomplexed aripiprazole.
In addition, in accordance with the present invention, a pharmaceutical formulation is provided which is formed of an inclusion complex of aripiprazole and a substituted-β-cyclodextrin, and a pharmaceutically acceptable carrier therefor.
In a preferred embodiment, the pharmaceutical formulation of the invention will be in the form of an aqueous parenteral or injectable formulation. However, the pharmaceutical formulation of the invention may be in other dosage forms such as lyophilized injectable, oral (for example tablets, capsules, elixirs and the like), transdermal or transmucosal forms or inhalation forms.
Further, in accordance with the present invention, a method is provided for administering injectable aripiprazole without causing unacceptable irritation at the site of injection wherein the above described injectable formulation is administered, preferably intramuscularly, to a patient in need of treatment.
Still further in accordance with the present invention, a method is provided for treating schizophrenia which includes the step of administering to a patient in need of treatment the above described formulation, preferably in injectable form, without causing undue irritation at the site of injection, whether it be at a muscular site or other site.
DETAILED DESCRIPTION OF THE INVENTION
Aripiprazole has poor water solubility and thus is difficult to formulate as an aqueous injectable. In accordance with the present invention, it as been found that the water-solubility of aripiprazole may be sufficiently increased to allow it to be formulated as an aqueous injectable by complexing aripiprazole with a substituted-β- cyclodextrin. In effect, the cyclodextrin inhibits precipitation of the aripiprazole at the site of injection. The aqueous injectable formulation containing the complex of aripiprazole and the substituted-β-cyclodextrin may be administered preferably intramuscularly without causing unacceptable irritation at the muscular site. This is indeed surprising and unexpected since, as indicated above, a host of water-miscible co-solvent systems and water-immiscible co-solvent systems have been found to be unacceptable as carriers for injectable aripiprazole formulations because of the unacceptable irritation profile of such formulations. On the other hand, the aqueous injectable formulation of the invention delivers aripiprazole without causing unacceptable irritation at the site of injection.
As will be seen hereinafter, the aripiprazole formulation in the form of an aqueous injectable will include an acid buffer and a base to adjust pH to desired levels.
The substituted-β-cyclodextrin suitable for use herein refers to sulfobutyl ether β-cyclodextrin (SBECD) and hydroxypropyl-β-cyclodextrin (HPBCD), with SBECD being preferred.
The term "undue irritation" or "unacceptable irritation" at the site of injection or at the muscular site refers to moderate to severe irritation which is unacceptable to the patient and thereby impacts unfavorably on patient compliance.
The term "reduced irritation" at the site of injection or at the muscular site refers to generally minimal to mild irritation which is acceptable to the patient and does not impact unfavorably on patient compliance.
The aripiprazole will form a complex with the substituted-β-cyclodextrin which complex may be dissolved in water to form an injectable formulation. However, physical mixtures of aripiprazole and the substituted-β-cyclodextrin are within the scope of the present invention as well.
The complex or the physical mixture may also be compressed into a tablet or may be filled into capsules.
The aripiprazole formulations of the invention may be formed of dry physical mixtures of aripiprazole and the substituted-β-cyclodextrin or dry inclusion complexes thereof which upon addition of water are reconstituted to form an aqueous injectable formulation. Alternatively, the aqueous injectable formulation may be freeze dried and later reconstituted with water. Thus, the inclusion complex in accordance with the invention, may be pre-formed, formed in situ or formed in vivo (in the gastrointestional tract or the buccal cavity). All of the above are contemplated by the present invention.
The aripiprazole formulation of the invention in the form of an aqueous injectable will include an acid buffer to adjust pH of the aqueous injection within the range from about 3.5 to about 5. Examples of acid buffers suitable for use herein include acids such as hydrochloric acid, sulfuric acid, phosphoric acid, hydrobromic acid and the like, and organic acids such as oxalic acid, maleic acid, fumaric acid, lactic acid, malic acid, tartaric acid, citric acid, benzoic acid, acetic acid, methanesulfonic acid, toluenesulfonic acid, benzenesulfonic acid, ethanesulfonic acid and the like. Acid salts of the above acids may be employed as well. Preferred acids are tartaric acid, citric acid, and hydrochloric acid. Most preferred is tartaric acid.
The injectable formulation of the invention will have a pH within the range from about 3.5 to about 5, preferably from about 4 to about 4.6, and most preferably about 4.3. In formulating the injectable, if necessary, the pH may be adjusted with a base such as an alkali metal hydroxide such as NaOH, KOH, or LiOH, preferably NaOH, or an alkaline earth metal hydroxide, such as Mg(OH)2 or Ca(OH)2. In preparing the aqueous injectable formulation of the invention, the substituted-β-cyclodextrin will be employed in a weight ratio to the aripiprazole within the range from about 5:1 to 400:1, preferably from about 10:1 to about 100:1. Each type of cyclodextrin employed requires a different ratio to inhibit or prevent precipitation of aripiprazole at the injection site. In preferred embodiments of the aqueous injectable of the invention, the substituted-β-cyclodextrin will be SBECD which will be employed in a weight ratio to aripiprazole within the range from about 5 : 1 to about 400 : 1 , preferably from about 20 : 1 to about 40 : 1. The cyclodextrin may be present in an amount greater than that needed to complex the aripiprazole since the additional cyclodextrin could aid in dissolution of the aripiprazole.
The aripiprazole will be present in the aqueous injectable formulation in an amount within the range from about 0.1 to about 2.5% by weight, preferably from about 0.2 to about 1.5 % by weight based on the total injectable formulation.
In preferred embodiments, the aripiprazole will be present in the aqueous injectable formulation to provide from about 1 to about 20 mg/mL of formulation, preferably from about 1.5 to about 8 mg/mL of formulation.
In more preferred embodiments, the formulations of the invention will provide
2 mg aripiprazole/mL, 5 mg/mL and 7.5 mg/mL. Fill volumes will preferably be 0.5 mL and 2 mL.
A preferred injectable formulation is as follows:
(1) aripiprazole - in an amount to provide from about 1.5 to about 8 mg/mL of solution.
(2) SBECD - in an amount from about 100 to about 200 mg/mL of solution. (3) acid buffer (preferably tartaric acid) - in an amount from about 7 to about 9 mg/mL of solution to adjust pH from about 3.5 to about 5.
(4) base to adjust pH, preferably an alkali metal hydroxide, preferably NaOH - in an amount to adjust pH from about 4 to 4.6
(5) water qs to 1 mL.
The aripiprazole injectable formulation of the invention may be prepared as follows: Tartaric acid or other acid buffer is dissolved in water for injection. The substituted-β-cyclodextrin (preferably SBECD) is dissolved in the acid buffer-water solution. Aripiprazole is then dissolved in the solution. The pH of the solution is adjusted to within the range from about 3.5 to about 5, preferably about 4.3 by adding base, such as sodium hydroxide or other alkali metal hydroxide or alkaline earth metal hydroxide. Additional water for injection is added to obtain the desired batch volume.
The resulting solution is aseptically filtered, for example, through a 0.22μ membrane filter and filled into vials. The vials are stopped and sealed and terminally sterilized.
The aqueous injectable formulation of the invention will provide an amount of aripiprazole of at least 2 mg aripiprazole/mL, preferably at least 5 mg aripiprazole/mL, when the amount of aripiprazole provided by the complex is measured at a cyclodextrin concentration of 5% w/v in water.
The aripiprazole formulations of the invention are used to treat schizophrenia in human patients. The preferred dosage employed for the injectable formulations of the invention will be a 2 ml injection containing 7.5 mg aripiprazole/mL or a dose of 15 mg given three times daily at two hour intervals. The injectable formulation is preferably administered intramuscularly although subcutaneous and intravenous injections are effective as well. The following example represents a preferred embodiment of the invention.
EXAMPLE
A clear colorless aripiprazole injectable solution (2 mg aripiprazole/mL, 4 mg/vial) essentially free of particulate matter by visual inspection was prepared as follows.
A stainless steel batching vessel was charged with an appropriate amount of water for inj ection USP .
With continuous stirring, 78 g tartaric acid granular USP and 1500 g sulfobutyl ether β -cyclodextrin (SBECD) was added to the batching vessel and was dissolved in the water.
Aripiprazole 20 g was added to the batching vessel and stirring was continued until the aripiprazole was dissolved.
Sodium hydroxide IN was added to the above solution to adjust the pH thereof to about 4.3.
Additional water for injection USP was added to the above solution to adjust to the final batch size to 10L with stirring.
The above solution was aseptically filtered through a 0.22 μM membrane filter into a sterilized container 4 mg amounts of the above solution were aseptically filled into sterilized vials which were then aseptically stoppered with sterilized stoppers to seal the vials.

Claims

What is claimed is:
1. An inclusion complex of aripiprazole in a substituted beta- cyclodextrin.
2. The inclusion complex as defined in Claim 1 wherein the β- cyclodextrin is sulfobutyl ether β-cyclodextrin (SBECD) or hydroxypropyl β- cyclodextrin (HPBCD).
3. The inclusion complex as defined in Claim 2 wherein the cyclodextrin is SBECD.
4. A pharmaceutical formulation comprising aripiprazole and a substituted β-cyclodextrin.
5. The formulation as defined in Claim 4 in the form of an injectable formulation.
6. The formulation as defined in Claim 4 wherein the substituted β- cyclodextrin is sulfobutyl ether β-cyclodextrin (SBECD) or hydroxypropyl-β- cyclodextrin (HPBCD).
7. The formulation is defined in Claim 4 comprising an aqueous injectable formulation having a pH within the range from about 3.5 to about 5.
8. The formulation as defined in Claim 7 including an acid buffer.
9. The formulation as defined in Claim 8 wherein the acid buffer is tartaric acid or a salt thereof, citric acid or a salt thereof, hydrochloric acid or a salt thereof, acetic acid or a salt thereof, maleic acid or a salt thereof, malic acid or a salt thereof, sulfuric acid or a salt thereof, toluenesulfonic acid or a salt thereof, benzenesulfonic acid or a salt thereof, naphthalenesulfonic acid or a salt thereof, or ethanesulfonic acid or a salt thereof.
10. The formulation as defined in Claim 9 further including a base to adjust pH of the aqueous formulation to within the range from about 3.5 to about 5.
11. The formulation as defined in Claim 8 wherein the substituted β- cyclodextrin is employed in a weight ratio to the aripiprazole within the range from about 10:1 to about 100:1.
12. The formulation as defined in Claim 8 wherein the acid buffer is employed in a weight ratio to the aripiprazole within the range from about 2: 1 to about 10:1.
13. The formulation as defined in Claim 5 wherein the aripiprazole is present in an amount to provide a dosage from about 1 to 10 mg aripiprazole/mL.
14. The formulation as defined in Claim 5 wherein the substituted β- cyclodextrin is SBECD and is present in a weight ratio to aripiprazole within the range from about 20 : 1 to about 40:1.
15. The formulation as defined in Claim 5 wherein the aripiprazole and the substituted-β-cyclodextrin are in the form of an inclusion complex.
16. The formulation as defined in Claim 5 wherein the formulation produces minimal irritation at the injection site.
17. An aqueous injectable formulation comprising aripiprazole, SBECD, tartaric acid, sodium hydroxide and water, said formulation having a pH within the range for about 4 to about 4.6.
18. The formulation as defined in Claim 17 comprising aripiprazole in an amount to provide from about 1.5 to about 8 mg/mL of formulation, SBECD in an amount with the range from about 100 to about 200 mg/mL; tartaric acid in an amount within the range from about 7 to about 9 mg/mL sodium hydroxide qs to adjust pH within the range from about 4 to about 4.6; and water qs to 1 mL.
19. The formulation as defined in Claim 18 wherein the aripiprazole and the SBECD form an inclusion complex.
20. The formulation as defined in Claim 17 designed for intramuscular administration without causing unacceptable irritation.
21. The formulation as defined in Claim 15 wherein the inclusion complex provides an amount of aripiprazole of at least 2 mg aripiprazole/mL when the amount of aripiprazole provided by said complex, is measured at a substituted-β-cyclodextrin concentration of 5% w/v in water.
22. A method for administering injectable aripiprazole to a patient in need of treatment without causing unacceptable irritation at the site of injection, which comprises administering to a patient in need of treatment the formulation as defined in Claim 17.
23. The method as defined in Claim 22 wherein the formulation is administered intramuscularly.
24. A method of treating schizophrenia, which comprises administering to a patient in need of treatment the formulation as defined in Claim 5 without causing undue irritation at the site of administration.
PCT/US2003/025573 2002-08-20 2003-08-14 Aripiprazole complex formulation and method Ceased WO2004017897A2 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
AU2003269965A AU2003269965B2 (en) 2002-08-20 2003-08-14 Aripiprazole complex formulation and method
UAA200502492A UA79984C2 (en) 2002-08-20 2003-08-14 Preparation on the basis of aripiprazole complex and use thereof
MXPA05001865A MXPA05001865A (en) 2002-08-20 2003-08-14 Aripiprazole complex formulation and method.
DK03751859T DK1542668T3 (en) 2002-08-20 2003-08-14 Formulation of aripiprazole complex and process
JP2004531017A JP4729306B2 (en) 2002-08-20 2003-08-14 Formulation and method of aripiprazole complex
EP03751859A EP1542668B1 (en) 2002-08-20 2003-08-14 Aripiprazole complex formulation and method
NZ537995A NZ537995A (en) 2002-08-20 2003-08-14 Inclusion complex of aripiprazole in a substituted b-cyclodextrin
AT03751859T ATE428423T1 (en) 2002-08-20 2003-08-14 ARIPIPRAZOLE COMPLEX FORMULATION AND METHODS
DE60327225T DE60327225D1 (en) 2002-08-20 2003-08-14 ARIPIPRAZOL COMPLEX FORMULATION AND METHOD
CA2495864A CA2495864C (en) 2002-08-20 2003-08-14 Aripiprazole complex formulation and method
BR0313602-7A BR0313602A (en) 2002-08-20 2003-08-14 Aripiprazole Complex Method and Formulation
YU20050118A RS51903B (en) 2002-08-20 2003-08-14 ARIPIPRAZOL COMPLEX FORMULATION AND PROCEDURE
HRP20050149AA HRP20050149B1 (en) 2002-08-20 2003-08-14 ARIPIPRAZOL COMPLEX FORMULATION AND PROCEDURE
SI200331586T SI1542668T1 (en) 2002-08-20 2003-08-14 Aripiprazole complex formulation and method
IL166623A IL166623A (en) 2002-08-20 2005-02-01 Aripiprazole complex, formulations comprising the same and uses thereof
NO20050661A NO333458B1 (en) 2002-08-20 2005-02-08 Aripiprazole Complex, such a drug for use as well as such for the treatment of schizophrenia
IS7701A IS2878B (en) 2002-08-20 2005-02-18 Aripiprazole formulation and method

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40471302P 2002-08-20 2002-08-20
US60/404,713 2002-08-20

Publications (2)

Publication Number Publication Date
WO2004017897A2 true WO2004017897A2 (en) 2004-03-04
WO2004017897A3 WO2004017897A3 (en) 2004-12-02

Family

ID=31946748

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/025573 Ceased WO2004017897A2 (en) 2002-08-20 2003-08-14 Aripiprazole complex formulation and method

Country Status (32)

Country Link
US (8) US7115587B2 (en)
EP (1) EP1542668B1 (en)
JP (1) JP4729306B2 (en)
KR (1) KR101043866B1 (en)
CN (1) CN100335047C (en)
AR (2) AR040887A1 (en)
AT (1) ATE428423T1 (en)
AU (1) AU2003269965B2 (en)
BR (1) BR0313602A (en)
CA (1) CA2495864C (en)
CY (1) CY1110331T1 (en)
DE (1) DE60327225D1 (en)
DK (1) DK1542668T3 (en)
ES (1) ES2322953T3 (en)
GE (1) GEP20063996B (en)
HR (1) HRP20050149B1 (en)
IL (1) IL166623A (en)
IS (1) IS2878B (en)
MX (1) MXPA05001865A (en)
MY (1) MY140793A (en)
NO (1) NO333458B1 (en)
NZ (1) NZ537995A (en)
PE (1) PE20040895A1 (en)
PL (1) PL212428B1 (en)
PT (1) PT1542668E (en)
RS (1) RS51903B (en)
RU (1) RU2342931C2 (en)
SI (1) SI1542668T1 (en)
TW (1) TWI307626B (en)
UA (1) UA79984C2 (en)
WO (1) WO2004017897A2 (en)
ZA (1) ZA200501064B (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005041937A3 (en) * 2003-10-23 2006-04-06 Otsuka Pharma Co Ltd Controlled release sterile injectable aripiprazole formulation and method
EP1903039A4 (en) * 2005-06-13 2010-09-22 Takeda Pharmaceutical INJECTION PRODUCT
WO2013100204A1 (en) * 2011-12-28 2013-07-04 Otsuka Pharmaceutical Co., Ltd. Pharmaceutical preparation comprising brexpiprazole and substituted beta - cyclodextrin
US8575172B2 (en) 2006-09-26 2013-11-05 Zysis Limited Pharmaceutical compositions of aripiprazole
US9457026B2 (en) 2007-07-31 2016-10-04 Otsuka Pharmaceutical Co., Ltd. Methods for producing aripiprazole suspension and freeze-dried formulation
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
CN109983025A (en) * 2016-08-02 2019-07-05 弗吉尼亚联邦大学 Composition comprising 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or a pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide
US10517951B2 (en) 2012-04-23 2019-12-31 Otsuka Pharmaceutical Co., Ltd. Injectable preparation
US10786517B2 (en) 2013-12-24 2020-09-29 Durect Corporation Uses of oxygenated cholesterol sulfates (OCS)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040170705A1 (en) * 2001-03-08 2004-09-02 Dusan Miljkovic Compositions and methods for non-insulin glucose uptake
SI1542668T1 (en) * 2002-08-20 2009-08-31 Bristol Myers Squibb Co Aripiprazole complex formulation and method
ATE529409T1 (en) * 2003-12-16 2011-11-15 Teva Pharma METHOD FOR PRODUCING CRYSTALLINE FORMS OF ARIPIPRAZOLE
US7714129B2 (en) 2003-12-16 2010-05-11 Teva Pharmaceutical Industries Ltd. Methods of preparing anhydrous aripiprazole form II
UA89513C2 (en) * 2004-12-03 2010-02-10 Элан Фарма Интернешнл Лтд. Nanoparticulate raloxifene hydrochloride composition
ES2326354B1 (en) * 2005-04-13 2010-07-08 Elan Pharma International Limited COMPOSITIONS OF CONTROLLED RELEASE AND NANOPARTICULATES THAT INCLUDE DERIVATIVES OF PROSTAGLANDINA.
AU2006255177A1 (en) * 2005-06-03 2006-12-14 Elan Pharma International, Limited Nanoparticulate imatinib mesylate formulations
US20100204178A1 (en) 2006-10-02 2010-08-12 James Cloyd Novel parenteral carbamazepine formulation
EA017290B1 (en) 2005-11-28 2012-11-30 Домейн Раша Инвестментс Лимитед COMPOSITIONS BASED ON HANAXOLON
CN101322709B (en) * 2007-06-12 2011-03-02 成都康弘药业集团股份有限公司 Medicament composition containing aripiprazole and preparation thereof
WO2009048947A1 (en) * 2007-10-09 2009-04-16 Board Of Regents, The University Of Texas System Methods of treatment of opioid tolerance, physical dependence, pain, and addiction with inhibitors of certain growth factor receptors
KR20110007095A (en) * 2008-03-21 2011-01-21 엘란 파마 인터내셔널 리미티드 Compositions and Methods of Use for Site-Specific Delivery of Imatinib
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
US8431576B2 (en) 2009-06-25 2013-04-30 Alkermes Pharma Ireland Limited Heterocyclic compounds for the treatment of neurological and psychological disorders
JP5732453B2 (en) 2009-06-25 2015-06-10 アルカーメス ファーマ アイルランド リミテッド Prodrugs of NH acidic compounds
WO2011023796A1 (en) 2009-08-31 2011-03-03 Abbott Healthcare Products B.V. Bifeprunox for treating addiction
KR101125210B1 (en) * 2009-09-11 2012-03-19 주식회사 대웅제약 Aripiprazole-Bentonite-AEA Nanohybrid, Pharmaceutical Composition Containing the Same, and Method for Preparing the Same
US20110140304A1 (en) * 2009-12-10 2011-06-16 Molecular Imprints, Inc. Imprint lithography template
US8592427B2 (en) 2010-06-24 2013-11-26 Alkermes Pharma Ireland Limited Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
US8383663B2 (en) * 2010-07-19 2013-02-26 Supratek Pharma Inc. Bendamustine anionic-catioinic cyclopolysaccharide compositions
LT2685979T (en) 2011-03-18 2016-12-12 Alkermes Pharma Ireland Limited Injectable pharmaceutical compositions comprising a water-insoluble anti-psychotic, sorbitan laurate and polysorbate 20
AU2012351747B2 (en) 2011-12-15 2016-05-12 Alkermes Pharma Ireland Limited Prodrugs of secondary amine compounds
US9751957B2 (en) 2012-02-15 2017-09-05 Cydex Pharmaceuticals, Inc. Manufacturing process for cyclodextrin derivatives
CA2867137C (en) 2012-03-19 2020-12-08 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising aripiprazole prodrugs and benzyl alcohol
ES2764383T3 (en) 2012-03-19 2020-06-03 Alkermes Pharma Ireland Ltd Pharmaceutical compositions comprising glycerol esters
WO2013142198A1 (en) 2012-03-19 2013-09-26 Alkermes Pharma Ireland Limited Pharmaaceutical compositions comprising fatty acid esters
KR101571670B1 (en) 2012-08-08 2015-11-25 주식회사 씨엠지제약 Formulation for orodispersible film comprising aripirazole
NZ631345A (en) 2012-09-19 2017-06-30 Alkermes Pharma Ireland Ltd Pharmaceutical compositions having improved storage stability
GR1008186B (en) 2013-04-22 2014-05-08 "Φαρματεν Α.Β.Ε.Ε.", Pharmaceutical composition comprising an atypical antipsychotic agent and method for the preparation thereof
JP6203682B2 (en) * 2013-07-10 2017-09-27 共和薬品工業株式会社 Aripiprazole-containing aqueous solution
US10525057B2 (en) 2013-09-24 2020-01-07 Otsuka Pharmaceutical Co., Ltd. Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
US20150086408A1 (en) * 2013-09-26 2015-03-26 General Electric Company Method of manufacturing a component and thermal management process
GR1008442B (en) 2014-01-16 2015-03-05 "Φαρματεν Α.Β.Ε.Ε.", Pharmaceutical formulation containing aripiprazole or salt thereof
BR112016021535A8 (en) 2014-03-20 2021-07-20 Alkermes Pharma Ireland Ltd kit comprising aripiprazole formulations having increased injection rates useful for the treatment of a central nervous system disorder and use
CN105078910B (en) * 2015-09-22 2018-05-22 成都欣捷高新技术开发有限公司 It is a kind of containing according to lyophilized oral formulations of piperazine azoles and preparation method thereof
WO2017066626A1 (en) 2015-10-16 2017-04-20 Marinus Pharmaceuticals, Inc. Injectable neurosteroid formulations containing nanoparticles
CN105616344A (en) * 2016-01-06 2016-06-01 万全万特制药江苏有限公司 Aripiprazole injection and preparation method therefor
BR112019002538A2 (en) 2016-08-11 2019-05-21 Ovid Therapeutics Inc. use of a pharmaceutical composition comprising an allosteric modulator, use of a pharmaceutical composition comprising garboxadol or a pharmaceutically acceptable salt thereof, and pharmaceutical composition for parenteral administration
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
CA3043979A1 (en) 2016-11-18 2018-05-24 Aicuris Anti-Infective Cures Gmbh Novel formulations of amidine substituted beta-lactam compounds on the basis of modified cyclodextrins and acidifying agents, their preparation and use as antimicrobial pharmaceutical compositions
WO2019102992A1 (en) * 2017-11-21 2019-05-31 積水化学工業株式会社 External skin preparation
CA3092335A1 (en) 2018-03-05 2019-09-12 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
CA3145923A1 (en) 2019-08-05 2021-02-11 David Czekai Ganaxolone for use in treatment of status epilepticus
WO2021113834A1 (en) 2019-12-06 2021-06-10 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treating tuberous sclerosis complex
EP4247340A4 (en) * 2020-11-18 2024-10-02 Bexson Biomedical, Inc. SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS BASED ON COMPLEXING AGENTS

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407079B1 (en) 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
JP2608788B2 (en) * 1988-10-31 1997-05-14 大塚製薬 株式会社 Schizophrenia remedy
JP2893175B2 (en) * 1988-10-31 1999-05-17 大塚製薬株式会社 Carbostyril derivative
KR0166088B1 (en) 1990-01-23 1999-01-15 . Cyclodextrin derivatives with increased water solubility and uses thereof
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
IT1263831B (en) 1993-01-29 1996-09-04 Paolo Chiesi MULTI-COMPONENT INCLUSION COMPLEXES WITH HIGH SOLUBILITY CONSTITUTED BY A BASIC-TYPE DRUG, AN ACID AND A CYCLODEXTRINE
JPH07165616A (en) * 1993-12-09 1995-06-27 Hisamitsu Pharmaceut Co Inc Complex composition of cyclodextrin and method for making complex
US5646131A (en) 1994-02-22 1997-07-08 The Arab Company For Drug Industries And Medical Applicances (Acdima) Method for solubilizing drugs using cyclodextrins and carboxylic acids
IT1269578B (en) 1994-04-22 1997-04-08 Chiesi Farma Spa MULTI-COMPONENT INCLUSION COMPLEXES WITH HIGH SOLUBILITY CONSISTING OF AN ACID TYPE DRUG, A CYCLODESTRINE AND A BASE.
UA57734C2 (en) 1996-05-07 2003-07-15 Пфайзер Інк. Arylheterocyclic inclusion complexes
JP4012994B2 (en) * 1996-05-08 2007-11-28 大塚製薬株式会社 Anxiolytic
JPH10194996A (en) 1996-12-25 1998-07-28 Janssen Pharmaceut Nv Acylated cyclodextrin-containing pharmaceutical composition
GB9713149D0 (en) 1997-06-21 1997-08-27 Pfizer Ltd Pharmaceutical formulations
GB9915231D0 (en) 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
CA2311734C (en) 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
MY129350A (en) * 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
AR033485A1 (en) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd MEDICINAL SUBSTANCE OF ARIPIPRAZOL OF LOW HYGROSCOPICITY AND PROCESS FOR THE PREPARATION OF THE SAME
SE0200301D0 (en) * 2002-02-01 2002-02-01 Axon Biochemicals Bv Thio-carbostyril derivative
SI1542668T1 (en) * 2002-08-20 2009-08-31 Bristol Myers Squibb Co Aripiprazole complex formulation and method
JP2006505579A (en) 2002-10-25 2006-02-16 ファイザー・プロダクツ・インク Accumulated formulations of aryl heterocyclic active drugs in suspension form

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7807680B2 (en) 2003-10-23 2010-10-05 Otsuka Pharmaceutical Co., Ltd. Controlled release sterile injectable aripiprazole formulation and method
US8030313B2 (en) 2003-10-23 2011-10-04 Otsuka Pharmaceutical Co., Ltd. Controlled release sterile injectable aripiprazole formulation and method
WO2005041937A3 (en) * 2003-10-23 2006-04-06 Otsuka Pharma Co Ltd Controlled release sterile injectable aripiprazole formulation and method
US8722679B2 (en) 2003-10-23 2014-05-13 Otsuka Pharmaceutical Co., Ltd. Controlled release sterile injectable aripiprazole formulation and method
US9763935B2 (en) 2003-10-23 2017-09-19 Otsuka Pharmaceutical Co., Ltd. Controlled release sterile injectable aripiprazole formulation and method
US8952013B2 (en) 2003-10-23 2015-02-10 Otsuka Pharmaceutical Co., Ltd. Controlled release sterile injectable aripiprazole formulation and method
EP1903039A4 (en) * 2005-06-13 2010-09-22 Takeda Pharmaceutical INJECTION PRODUCT
US8575172B2 (en) 2006-09-26 2013-11-05 Zysis Limited Pharmaceutical compositions of aripiprazole
US9457026B2 (en) 2007-07-31 2016-10-04 Otsuka Pharmaceutical Co., Ltd. Methods for producing aripiprazole suspension and freeze-dried formulation
AU2012360716B2 (en) * 2011-12-28 2017-08-17 Otsuka Pharmaceutical Co., Ltd. Pharmaceutical preparation comprising brexpiprazole and substituted beta - cyclodextrin
CN104023750A (en) * 2011-12-28 2014-09-03 大塚制药株式会社 Pharmaceutical preparations containing ΒREXPIPRAZOLE and substituted beta-cyclodextrins
CN107261153A (en) * 2011-12-28 2017-10-20 大塚制药株式会社 The pharmaceutical preparation of beta cyclodextrin comprising Β REXPIPRAZOLE and substitution
WO2013100204A1 (en) * 2011-12-28 2013-07-04 Otsuka Pharmaceutical Co., Ltd. Pharmaceutical preparation comprising brexpiprazole and substituted beta - cyclodextrin
US10517951B2 (en) 2012-04-23 2019-12-31 Otsuka Pharmaceutical Co., Ltd. Injectable preparation
US12016927B2 (en) 2012-04-23 2024-06-25 Otsuka Pharmaceutical Co., Ltd. Injectable preparation
US11097007B2 (en) 2012-04-23 2021-08-24 Otsuka Pharmaceutical Co., Ltd. Injectable preparation
US11638757B2 (en) 2012-04-23 2023-05-02 Otsuka Pharmaceutical Co., Ltd. Injectable preparation
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
EP3610890A1 (en) 2012-11-14 2020-02-19 The Johns Hopkins University Methods and compositions for treating schizophrenia
US10624875B2 (en) 2012-11-14 2020-04-21 The Johns Hopkins University Methods and compositions for treating schizophrenia
US11612609B2 (en) 2013-12-24 2023-03-28 Durect Corporation Uses of oxygenated cholesterol sulfates (OCS)
US10786517B2 (en) 2013-12-24 2020-09-29 Durect Corporation Uses of oxygenated cholesterol sulfates (OCS)
CN109983025A (en) * 2016-08-02 2019-07-05 弗吉尼亚联邦大学 Composition comprising 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or a pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide
EP4101861A1 (en) * 2016-08-02 2022-12-14 Virginia Commonwealth University Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide
CN109983025B (en) * 2016-08-02 2023-04-04 弗吉尼亚联邦大学 Composition comprising 5-cholestene-3,25-diol, 3-sulfate or salt thereof and at least one cyclic oligosaccharide
US11406646B2 (en) 2016-08-02 2022-08-09 Virginia Commonwealth University Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide
AU2022204217B2 (en) * 2016-08-02 2024-04-04 Durect Corporation Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide
EP3494125A4 (en) * 2016-08-02 2020-04-01 Virginia Commonwealth University COMPOSITIONS COMPRISING 5-CHOLESTENE-3, 25-DIOL, 3-SULFATE (25 H3S) OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND AT LEAST ONE CYCLIC OLIGOSACCHARIDE
US12226423B2 (en) 2016-08-02 2025-02-18 Virginia Commonwealth University Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25HC3S) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide

Also Published As

Publication number Publication date
AR102101A2 (en) 2017-02-01
TW200405813A (en) 2004-04-16
UA79984C2 (en) 2007-08-10
PL212428B1 (en) 2012-09-28
NO20050661L (en) 2005-03-16
KR20050040927A (en) 2005-05-03
CA2495864A1 (en) 2004-03-04
SI1542668T1 (en) 2009-08-31
TWI307626B (en) 2009-03-21
JP4729306B2 (en) 2011-07-20
US20090186903A1 (en) 2009-07-23
GEP20063996B (en) 2006-12-11
PE20040895A1 (en) 2004-11-20
DK1542668T3 (en) 2009-07-20
US7115587B2 (en) 2006-10-03
CY1110331T1 (en) 2015-01-14
ZA200501064B (en) 2006-12-27
CN100335047C (en) 2007-09-05
ES2322953T3 (en) 2009-07-02
US20150328335A1 (en) 2015-11-19
AU2003269965B2 (en) 2008-02-21
RS20050118A (en) 2007-06-04
US20130045981A1 (en) 2013-02-21
US7550445B2 (en) 2009-06-23
US20120053145A1 (en) 2012-03-01
IS2878B (en) 2014-04-15
IL166623A0 (en) 2006-01-15
US8999952B2 (en) 2015-04-07
US20060234979A1 (en) 2006-10-19
NZ537995A (en) 2007-11-30
RS51903B (en) 2012-02-29
JP2006501240A (en) 2006-01-12
BR0313602A (en) 2005-06-21
EP1542668A2 (en) 2005-06-22
AU2003269965A1 (en) 2004-03-11
WO2004017897A3 (en) 2004-12-02
MXPA05001865A (en) 2005-06-03
KR101043866B1 (en) 2011-06-22
IL166623A (en) 2011-07-31
US20040077594A1 (en) 2004-04-22
IS7701A (en) 2005-02-18
MY140793A (en) 2010-01-15
US20110160224A1 (en) 2011-06-30
US20140235574A1 (en) 2014-08-21
CN1674882A (en) 2005-09-28
PT1542668E (en) 2009-06-09
DE60327225D1 (en) 2009-05-28
HRP20050149B1 (en) 2014-09-12
ATE428423T1 (en) 2009-05-15
EP1542668B1 (en) 2009-04-15
NO333458B1 (en) 2013-06-10
CA2495864C (en) 2011-09-27
EP1542668A4 (en) 2007-10-17
HRP20050149A2 (en) 2005-10-31
PL374798A1 (en) 2005-10-31
RU2005107471A (en) 2005-09-10
AR040887A1 (en) 2005-04-20
RU2342931C2 (en) 2009-01-10

Similar Documents

Publication Publication Date Title
EP1542668B1 (en) Aripiprazole complex formulation and method
JP6246715B2 (en) Pharmaceutical formulation comprising brexpiprazole and substituted β-cyclodextrin
NZ626379B2 (en) Pharmaceutical preparation comprising brexpiprazole and substituted beta - cyclodextrin

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 1200500194

Country of ref document: VN

Ref document number: P-2005/0118

Country of ref document: YU

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003269965

Country of ref document: AU

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 166623

Country of ref document: IL

Ref document number: 537995

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2005/01064

Country of ref document: ZA

Ref document number: 200501064

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 472/DELNP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2003751859

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: P20050149A

Country of ref document: HR

Ref document number: PA/a/2005/001865

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2495864

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 374798

Country of ref document: PL

Ref document number: 20038195534

Country of ref document: CN

Ref document number: 1020057002789

Country of ref document: KR

Ref document number: 2004531017

Country of ref document: JP

Ref document number: 05015234

Country of ref document: CO

ENP Entry into the national phase

Ref country code: GE

Ref document number: GE P

WWE Wipo information: entry into national phase

Ref document number: 8703

Country of ref document: GE

ENP Entry into the national phase

Ref document number: 2005107471

Country of ref document: RU

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1020057002789

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2003751859

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1-2005-500277

Country of ref document: PH